-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
2
-
-
80455123686
-
Pathology of lung cancer
-
Travis WD. Pathology of lung cancer. Clin Chest Med 2011;32:669-92.
-
(2011)
Clin Chest Med
, vol.32
, pp. 669-692
-
-
Travis, W.D.1
-
3
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
-
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
Feng, J.4
Liu, X.Q.5
Wang, C.6
-
4
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
Sugawara, S.4
Oizumi, S.5
Isobe, H.6
-
5
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
-
6
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
Shaw, A.T.4
Solomon, B.5
Maki, R.G.6
-
7
-
-
13244262942
-
Adjuvant treatment of lung cancer: Current status and potential applications of new regimens
-
Le Chevalier T, Lynch T. Adjuvant treatment of lung cancer: current status and potential applications of new regimens. Lung Cancer 2004;46:S33-9.
-
(2004)
Lung Cancer
, vol.46
, pp. S33-S39
-
-
Le Chevalier, T.1
Lynch, T.2
-
8
-
-
33747847740
-
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant navelbine international trialist association [ANITA]): A randomised controlled trial
-
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
-
(2006)
Lancet Oncol
, vol.7
, pp. 719-727
-
-
Douillard, J.Y.1
Rosell, R.2
De Lena, M.3
Carpagnano, F.4
Ramlau, R.5
Gonzáles-Larriba, J.L.6
-
9
-
-
20544455590
-
Vinorelbine plus cisplatin vs. Observation in resected non-small-cell lung cancer
-
Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
-
(2005)
N Engl J Med
, vol.352
, pp. 2589-2597
-
-
Winton, T.1
Livingston, R.2
Johnson, D.3
Rigas, J.4
Johnston, M.5
Butts, C.6
-
10
-
-
49049109683
-
Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group
-
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3552-3559
-
-
Pignon, J.P.1
Tribodet, H.2
Scagliotti, G.V.3
Douillard, J.Y.4
Shepherd, F.A.5
Stephens, R.J.6
-
11
-
-
62849096370
-
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebocontrolled trial
-
Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebocontrolled trial. Lancet 2009;373:1097-104.
-
(2009)
Lancet
, vol.373
, pp. 1097-1104
-
-
Dematteo, R.P.1
Ballman, K.V.2
Antonescu, C.R.3
Maki, R.G.4
Pisters, P.W.5
Demetri, G.D.6
-
12
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer, C.E.5
Davidson, N.E.6
-
13
-
-
84905029258
-
Comprehensive molecular profiling of lung adenocarcinoma
-
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
-
(2014)
Nature
, vol.511
, pp. 543-550
-
-
-
14
-
-
84866894408
-
Comprehensive genomic characterization of squamous cell lung cancers
-
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489: 519-25.
-
(2012)
Nature
, vol.489
, pp. 519-525
-
-
-
15
-
-
84880507665
-
Mutational heterogeneity in cancer and the search for new cancerassociated genes
-
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013;499:214-8.
-
(2013)
Nature
, vol.499
, pp. 214-218
-
-
Lawrence, M.S.1
Stojanov, P.2
Polak, P.3
Kryukov, G.V.4
Cibulskis, K.5
Sivachenko, A.6
-
16
-
-
84861203302
-
EGFR-mutated oncogeneaddicted non-small cell lung cancer: Current trends and future prospects
-
Soria JC, Mok TS, Cappuzzo F, Janne PA. EGFR-mutated oncogeneaddicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 2012;38:416-30.
-
(2012)
Cancer Treat Rev
, vol.38
, pp. 416-430
-
-
Soria, J.C.1
Mok, T.S.2
Cappuzzo, F.3
Janne, P.A.4
-
17
-
-
77953541527
-
SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
-
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
-
(2010)
Lancet Oncol
, vol.11
, pp. 521-529
-
-
Cappuzzo, F.1
Ciuleanu, T.2
Stelmakh, L.3
Cicenas, S.4
Szczésna, A.5
Juhász, E.6
-
18
-
-
84890896341
-
Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study
-
Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 2013;31: 3320-6.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3320-3326
-
-
Goss, G.D.1
O'Callaghan, C.2
Lorimer, I.3
Tsao, M.S.4
Masters, G.A.5
Jett, J.6
-
19
-
-
84919339224
-
A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results
-
(suppl; abstr 7501)
-
Kelly K, Altroki NK, Eberhardt WEE, O'Brien MER, Spigel DR, Crino L, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J Clin Oncol 32:5s, 2014 (suppl; abstr 7501).
-
(2014)
J Clin Oncol
, vol.32
, Issue.S5
-
-
Kelly, K.1
Altroki, N.K.2
Eberhardt, W.E.E.3
O'Brien, M.E.R.4
Spigel, D.R.5
Crino, L.6
-
20
-
-
84918804764
-
Firstline crizotinib versus chemotherapy in ALK-positive lung cancer
-
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
-
(2014)
N Engl J Med
, vol.371
, pp. 2167-2177
-
-
Solomon, B.J.1
Mok, T.2
Kim, D.W.3
Wu, Y.L.4
Nakagawa, K.5
Mekhail, T.6
-
21
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
Kim, D.W.2
Nakagawa, K.3
Seto, T.4
Crinó, L.5
Ahn, M.J.6
-
22
-
-
70349336416
-
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
-
Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4247-4253
-
-
Shaw, A.T.1
Yeap, B.Y.2
Mino-Kenudson, M.3
Digumarthy, S.R.4
Costa, D.B.5
Heist, R.S.6
-
23
-
-
84655170204
-
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma
-
Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thora Oncol 2012;7:90-7.
-
(2012)
J Thora Oncol
, vol.7
, pp. 90-97
-
-
Yang, P.1
Kulig, K.2
Boland, J.M.3
Erickson-Johnson, M.R.4
Oliveira, A.M.5
Wampfler, J.6
|